TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9125088
Drug: Chemical/Biological Combat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical/Biological Combat Suit (CBCS)
Study: 2979237
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized testosterone (200 mg t.d.s.)
Study: 27049056
Drug: Test spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test spironolactone tablet formulation (100 mg) under fasting condition
Study: 27049056
Drug: Test spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test spironolactone tablet formulation (100 mg) under fed condition
Study: 27049056
Drug: Reference spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference spironolactone tablet formulation (100 mg) under fasting condition
Study: 27049056
Drug: Reference spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference spironolactone tablet formulation (100 mg) under fed condition
Study: 23857878
Drug: Various drugs
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various drugs (90 drugs assessed)
Study: 23857878
Drug: Trimipramine (tricyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine (tricyclic antidepressant)
Study: 6378303
Drug: Clomipramine (tricyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (tricyclic antidepressant)
Study: 23857878
Drug: Chlorpromazine (antipsychotic)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (antipsychotic)
Study: 23857878
Drug: Sotalol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (beta blocker)
Study: 23857878
Drug: Itraconazole (antifungal)
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole (antifungal)
Study: 23857878
Drug: Phenylpropanolamine (decongestant/anorectic)
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylpropanolamine (decongestant/anorectic)
Study: 1525787
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg once daily
Study: 8040678
Drug: Epirubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin and dexrazoxane (600/120 mg/m2, 900/120 mg/m2, 900/135 mg/m2, 900/150 mg/m2, 1,200/135 mg/m2)
Study: 2493868
Drug: Counselling by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselling by health visitors (8 weekly visits)
Study: 9890791
Drug: Dipropylacetate (Depakine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipropylacetate (Depakine, 20 mg/kg)
Study: 9890791
Drug: Phenobarbital (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (5 mg/kg)
Study: 9890791
Drug: Primidone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primidone (25 mg/kg)
Study: 28193663
Drug: Patient-targeted education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-targeted education about the etiology of URTIs, the role of antibiotics, and consequences of inappropriate antibiotic use.
Study: 9175371
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic combined with piroxicam eye drops
Study: 9175371
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic eye drops alone
Study: 1283661
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (EACA) 5 g administered after induction of anesthesia and 2 g/h during surgery
Study: 1283661
Drug: Aprotinin (APROT)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin (APROT) 2.10(6) UIK administered after induction of anesthesia and 5.10(5) UIK/h during surgery
Study: 30700474
Drug: Perioperative CapeOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative CapeOX chemotherapy (up to four cycles every 3 weeks) plus radical surgery plus up to four cycles of postoperative chemotherapy
Study: 30700474
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (up to eight cycles after radical surgery)
Study: 27062400
Drug: Family Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Based Treatment (FBT)
Study: 27062400
Drug: Systemic Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic Family Therapy (SyFT)
Study: 22955513
Drug: Moderate fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate fat ingestion (MF) - 0.7 g of fat/kg body weight
Study: 22955513
Drug: Low fat
Normalized name: Low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat ingestion (LF) - 0.4 g of fat/kg body weight
Study: 17914085
Drug: Subcutaneous granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous granisetron (3 mg)
Study: 17914085
Drug: Intravenous granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous granisetron (3 mg)
Study: 16208801
Drug: Oscillating/pulsating power
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oscillating/pulsating power toothbrush (Oral‐B ProfessionalCare 7000; PC 7000)
Study: 3155240
Drug: Immunoglobulin treatment
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin treatment
Study: 10419244
Drug: High-dose steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose steroids treatment
Study: 30223911
Drug: ADT+brexpiprazole 1-3
Normalized name: brexpiprazole 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT+brexpiprazole 1-3 mg/day
Study: 26458986
Drug: Movi-Kids intervention
Normalized name: Mederma for Kids
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Movi-Kids intervention (three hour-long sessions of recreational non-competitive physical activity after school, weekly; educational materials for parents and teachers; playground modifications)
Study: 21819824
Drug: Standard monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard monitoring by the Motor Vehicle Administration (Control)
Study: 11583878
Drug: Constant medical
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant medical therapy
Study: 7534847
Drug: Preventive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive therapy with pantripin and contrykal
Study: 3309812
Drug: Pefloxacin infusion
Normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin infusion for one hour
Study: 31754703
Drug: Darunavir/ritonavir (800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir (800/100 mg) + raltegravir (400 mg)
Study: 31754703
Drug: Darunavir/ritonavir (800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir (800/100 mg) + tenofovir disoproxil fumarate/emtricitabine (245/200 mg once daily)
Study: 19861543
Drug: 3.0-g bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0-g bovine lactoferrin (bLF) daily for 12 months
Study: 19861543
Drug: 1.5-g bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5-g bovine lactoferrin (bLF) daily for 12 months
Study: 16518959
Drug: Enfuvirtide (ENF)
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enfuvirtide (ENF) in combination with lopinavir/ritonavir, efavirenz, lamivudine, and tenofovir
Study: 16518959
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no enfuvirtide) with the same four-drug regimen
Study: 9407455
Drug: AST-120 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 (6 g/day) concurrent with low protein diet (LPD)
Study: 8508355
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with vincristine (VCR)
Study: 8508355
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy without vincristine (VCR)
Study: 8508355
Drug: 12 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 courses of maintenance‐intensification therapy
Study: 8508355
Drug: 4 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 courses of maintenance‐intensification therapy
Study: 3479420
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg orally twice daily for 14 days
Study: 3479420
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg orally twice daily for 14 days
Study: 25616042
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) at doses of 200-400 mg/kg
Study: 25616042
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) at doses of 600-800 mg/kg
Study: 17295082
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam irradiation (EBI) plus antiplatelet therapy
Study: 15170163
Drug: Sequential skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential skin biopsies
Study: 11585352
Drug: Continuous ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ibandronate 2.5 mg daily (n = 81)
Study: 11585352
Drug: Intermittent ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent ibandronate 20 mg every other day for the first 24 days (n = 78)
Study: 11585352
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (continuous and intermittent)
Study: 8555958
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (NNS)
Study: 2496789
Drug: Nimodipine 60
Normalized name: nimodipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 60 mg orally every four hours for 21 days
Study: 723760
Drug: Clofibate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibate (2 X 1 g)
Study: 723760
Drug: Bezafibrate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (3 X 150 mg)
Study: 29725824
Drug: Intervention spread
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention spread with 2.0 g/day plant sterols and 1.0 g/day EPA+DHA from fish oil
Study: 25127179
Drug: Face-to-face ACT
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face ACT treatment
Study: 22376210
Drug: Test gel
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test gel (anesthetic gel)
Study: 9706859
Drug: Test gel
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test gel
Study: 17495015
Drug: Adapted-dose azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adapted-dose azathioprine therapy (adjusted to maintain 6-TGN concentrations between 250 and 400 pmol/8 x 10(8) erythrocytes)
Study: 17495015
Drug: Standard-dose azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose azathioprine therapy (2.5 mg/kg/day)
Study: 17495015
Drug: Adapted-dose azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adapted-dose azathioprine therapy
Study: 17495015
Drug: Standard-dose azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose azathioprine therapy
Study: 8313125
Drug: Peripheral IVN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral IVN system with fine-bore silicone catheter and lipid-based nutrient solutions
Study: 2478330
Drug: Antithrombin III/low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin III/low-dose heparin (ATIII/LDH) regimen (3000 units loading dose followed by 2000 units daily and 5000 units of LDH twice daily)
Study: 2478330
Drug: Low-molecular-weight dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight dextran (LMWD) (10 ml/kg x 12 hours loading dose followed by 7 ml/kg x 24 hours maintenance dose)
Study: 786311
Drug: WA 335
Approvals — FDA: no, EMA: no, PMDA: no
Description: WA 335 (3 X 1 mg/die)
Study: 786311
Drug: Amitriptyline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (3 X 50 mg/die)
Study: 28235726
Drug: CCRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCRT plus AC (adjuvant cisplatin 80 mg/m2 and fluorouracil 800 mg/m2/d for 120 h every 4 weeks for three cycles)
Study: 22012289
Drug: II and
Normalized name: coagulation factor IX, II, VII and X in combination
DrugBank: Factor IX Complex (Human) (DB11330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: II and IH nerve block with 10 mL of 0.75% ropivacaine and surgical wound infiltration with 10 mL of 0.75% ropivacaine
Study: 22012289
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 15 mg hyperbaric 0.5% bupivacaine (Control Group)
Study: 17403400
Drug: laxative (magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: laxative (magnesium oxide + disodium phosphate)
Study: 15576019
Drug: 1.5 x
Normalized name: lisocabtagene maraleucel 1.5 x 10exp6 to 70 x 10exp6 cell/mL INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 x 10(6) IU of albumin-free recombinant streptokinase (rSK) in a one-hour intravenous infusion
Study: 9609895
Drug: Perflenapent emulsion
Normalized name: perflenapent
DrugBank: Perflenapent (DB11625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perflenapent emulsion (0.05 mL/kg)
Study: 31123001
Drug: Individualised antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised antiplatelet therapy based on pharmacogenetic information and clinical features (pharmacogenetic group)
Study: 24618231
Drug: Concentrated ambient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated ambient coarse particles (CAP; 76.2 ± 51.5 μg/m(3))
Study: 19093773
Drug: Autologous tumor
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumor cell-derived vaccines
Study: 19093773
Drug: Allogeneic tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic tumor cell-derived vaccines
Study: 18192950
Drug: Vasoactive agents
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive agents (inotropes and pressor agents)
Study: 15167885
Drug: Early Total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Total Parenteral Nutrition (ETPN)
Study: 15167885
Drug: Late Total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late Total Parenteral Nutrition (LTPN)
Study: 11669169
Drug: Cyclosporine (CSA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CSA) 3 mg/kg/day
Study: 11669169
Drug: Sulfasalazine (SSZ)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine (SSZ) 2,000 mg/day
Study: 2847578
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium aerosol (2 inhalations; 2 mg/inhalation)
Study: 31257987
Drug: Separate imputation
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate imputation by treatment group
Study: 28213388
Drug: Dopamine donor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine donor pretreatment (4 µg/kg per minute continuous infusion)
Study: 28213388
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dopamine infusion)
Study: 28213388
Drug: Dopamine donor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine donor pretreatment with infusion time of 7.1 hours
Study: 24613349
Drug: Atacicept 150
Normalized name: Atacicept
DrugBank: Atacicept (DB06399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept 150 mg
Study: 23391369
Drug: AZD9668 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9668 (150 mg single dose, 70 mg twice daily multiple doses)
Study: 19117833
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D and calcium supplementation (100,000 IU bimonthly and 1 g/day calcium)
Study: 17674917
Drug: Combined 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 5-fluorouracil (5-FU) and low-molecular-weight heparin (LMWH) with silicone oil
Study: 17674917
Drug: Silicone oil
Normalized name: SILICONE OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone oil without adjunctive medication (control group)
Study: 14724665
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg/day plus metoprolol 25 mg/day (group M)
Study: 14724665
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg/day plus placebo (group P)
Study: 9278651
Drug: Enoxaparin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin, 40 mg once daily, beginning 2 hours before surgery
Study: 9278651
Drug: Unfractionated low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Unfractionated low-dose heparin, three times daily
Study: 8314960
Drug: 1.0 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ng/ml EGF
Study: 8314960
Drug: 10.0 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0 ng/ml EGF
Study: 3578401
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive preparations (seven types)
Study: 29112070
Drug: Ritonavir-boosted protease
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted protease inhibitor (PI/r)
Study: 26261074
Drug: 200 U
Normalized name: lipase 1200 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 U BTX‐A intradetrusor injections excluding the trigone (Control group)
Study: 26261074
Drug: 160 U
Normalized name: hyaluronidase, human recombinant 160 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 U intradetrusor and 40 U intratrigonal injections (Experimental group)
Study: 8024910
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (ramipril)
Study: 12864879
Drug: Dihydropyridine calcium
Normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydropyridine calcium channel blocker (DHP-CCB, amlodipine)
Study: 12819322
Drug: Beta-blocker (metoprolol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (metoprolol)
Study: 11472003
Drug: Sequential mode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential mode ablation technique
Study: 15640848
Drug: Influenza split
Normalized name: INFLUENZA SPLIT VIRUS '95-'96 VIL 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza split vaccine
Study: 9258527
Drug: Influenza split
Normalized name: INFLUENZA SPLIT VIRUS '95-'96 VIL 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza split vaccine + Pneumococcal 23-valent vaccine
Study: 9258527
Drug: Pneumococcal 23-valent
Normalized name: Pneumococcal 23-valent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal 23-valent vaccine (administered simultaneously with influenza vaccine)
Study: 9258527
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Influenza vaccine alone)
Study: 7943888
Drug: Film-forming preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-forming preparation 'Lifusol' for catheter fixation
Study: 2945783
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human atrial natriuretic peptide (i.v. bolus of 25 micrograms followed by a 6‐hour infusion of 25 micrograms/hr)
Study: 2945783
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human atrial natriuretic peptide (i.v. bolus of 175 micrograms followed by a 6‐hour infusion of 100 micrograms/hr)
Study: 26742001
Drug: Live Attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live Attenuated Influenza Vaccine (LAIV), administered to 77 children, analyzed 63 children after vaccination.
Study: 21985488
Drug: Pentoxifylline (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (800 mg/day, intravenous infusion and oral supplementation)
Study: 19671203
Drug: Capsinoids (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsinoids (1 mg)
Study: 19671203
Drug: Capsinoids (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsinoids (3 mg)
Study: 19671203
Drug: Capsinoids (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsinoids (6 mg)
Study: 29381803
Drug: Capsinoids (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsinoids (12 mg)
Study: 15838406
Drug: Medical care
Normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical care with physical therapy (MDPt)